HI-TRON Mainz

A Helmholtz-Institute of the DKFZ

Helmholtz-Institute for Translational Oncology Mainz

Learn more

A Joint-Venture

OUR INSTITUTE

The German Cancer Research Center (DKFZ) joins forces with the Research Institute for Translational Oncology (TRON gGmbH), the University Medical Center Mainz (UMC), and the Johannes Gutenberg University Mainz (JGU) to create a new institute.

Learn more

Fighting Cancer

OUR MISSION

Combining the internationally outstanding expertise of our partners to deliver personalized immunotherapy against cancer.

Learn more

Advancing the frontiers of research on personalized immunotherapy

OUR RESEARCH

Using cutting-edge science, technology and computational methods to fight against cancer.

Learn more

A Helmholtz-Institute of the DKFZ
OUR INSTITUTE
OUR MISSION
OUR RESEARCH

The Helmholtz-Institute for Translational Oncology Mainz (HI-TRON Mainz) is a joint venture of the German Cancer Research Center (DKFZ) with the Research Institute for Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (TRON gGmbH), the University Medical Center Mainz (UMC) and the Johannes Gutenberg University Mainz (JGU).

We aim to combine the internationally outstanding expertise of these partners in the field of personalized immunotherapy in Mainz with the comprehensive spectrum of cutting-edge cancer research at the DKFZ. HI-TRON Mainz strives to position itself among the world-leading centers for personalized cancer immuno-oncology.

News

March 2025

Spotlight: Important Topics & Updates

In our Spotlight section, we highlight key topics that matter to us and our community. From major updates like our new building to important discussions on issues like animal testing, we take a closer look at what’s shaping our work and values. Stay informed with our latest insights.

February 2025

Update: New building

Our construction site is changing every day. And progress is being made

Photo of an excavator on the new building site

September 2024

Congratulations to the teams of Niels Halama and Ugur Sahin!

They have successfully obtained project funding within the highly competitive DKTK Joint Funding Call "INNOVATION 2024" on the topic of "mRNA-Based Strategies for Targeted TME Modulation and Enhanced Antitumor Immunity". We look very much forward to working with our colleagues from Essen/Düsseldorf, Frankfurt/Mainz and Heidelberg.

Spotlight: Important Topics & Updates
Update: New building
Congratulations to the teams of Niels Halama and Ugur Sahin!